Genética y Terapéutica en Cáncer de Próstata |

Publicaciones

2025

Melero, I, Luken, MD, de Velasco, G, Garralda, E, Martin-Liberal, J, Joerger, M, Alonso, G, Goebeler, ME, Schuler, M, Koenig, D, Dummer, R, Reig, M, Ruiz, MER, Calvo, E, Esteban-Villarrubia, J, Oberoi, A, Sabat, P, Soto-Castillo, JJ, Koster, KL, Saavedra, O, Sayehli, C, Gromke, T, Laeubli, H, Ramelyte, E, Fortuny, M, Landa-Magdalena, A, Moreno, I, Torres-Jimenez, J, Hernando-Calvo, A, Hess, D, Racca, F, Richly, H, Schmitt, AM, Eggenschwiler, C, Sanduzzi-Zamparelli, M, Vilalta-Lacarra, A, Trojan, J, Koch, C, Galle, PR, Foerster, F, Trajanoski, Z, Hackl, H, Gogolla, F, Koll, FJ, Wild, P, Chun, FKH, Reis, H, Lloyd, P, Machacek, M, Gajewski, TF, Fridman, WH, Eggermont, AMM, Bargou, R, Schoeniger, S, Rueschoff, J, Tereshchenko, A, Zink, C, da Silva, A, Lichtenegger, FS, Akdemir, J, Ruediger, M, L'Huillier, P, Dutta, A, Haake, M, Auckenthaler, A, Gjorgjioska, A, Roessler, B, Hermann, F, Liebig, M, Reichhardt, D, Schuberth-Wagner, C, Wischhusen, J, Fettes, P, Auer, M, Klar, K, Leo, E (2025).

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Nature. Article. 637(8048).
[doi:10.1038/s41586-024-08305-z]

Sarno, F, Tenorio, J, Perea, S, Medina, L, Pazo-Cid, R, Juez, I, Garcia-Carbonero, R, Feliu, J, Guillen-Ponce, C, Lopez-Casas, PP, Guerra, C, Duran, Y, López-Acosta, JF, Alonso, C, Esquivel, E, Dopazo, A, Akshinthala, D, Muthuswamy, SK, Lapunzina, P, Bockorny, B, Hidalgo, M (2025).

A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial

CLINICAL CANCER RESEARCH. Article. 31(2):278-287.
[doi:10.1158/1078-0432.CCR-23-4026]

2024

Saad, F, Vjaters, E, Shore, N, Olmos, D, Xing, NZ, Gomes, AJPD, Mota, ACD, Salman, P, Jievaltas, M, Ulys, A, Jakubovskis, M, Kopyltsov, E, Han, WQ, Nevalaita, L, Testa, I, Le Berre, MA, Kuss, I, Haresh, KP (2024).

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

JOURNAL OF CLINICAL ONCOLOGY. Article. 42(36).
[doi:10.1200/JCO-24-01798]

Esteban-Villarrubia, J, Ballesteros, PA, Martín-Serrano, M, Vico, MR, Funes, JM, de Velasco, G, Castro, E, Olmos, D, Castellano, D, González-Billalabeitia, E (2024).

Mechanisms of Immune Evasion in PTEN Loss Prostate Cancer

Immuno. Review. 4(4):444-460.
[doi:10.3390/immuno4040028]

Manso, LS, Alfranca, A, Moreno-Pérez, I, Ruiz-Vico, M, Velasco, C, Toquero, P, Pacheco, M, Zapatero, A, Aldave, D, Celada, G, Albers, E, de la Maza, MDF, García, J, Castro, E, Olmos, D, Colomer, R, Romero-Laorden, N (2024).

Immunome profiling in prostate cancer: a guide for clinicians

Frontiers in immunology. Review. 15:1398109-1398109.
[doi:10.3389/fimmu.2024.1398109]

Iglesias-Matesanz, P, Lacalle-Gonzalez, C, Lopez-Blazquez, C, Otieno, MO, Garcia-Foncillas, J, Martinez-Useros, J (2024).

Glutathione Peroxidases: An Emerging and Promising Therapeutic Target for Pancreatic Cancer Treatment

Antioxidants. Review. 13(11).
[doi:10.3390/antiox13111405]

González-Ginel, I, Hernández-Arroyo, M, García-Rayo, C, Gómez-del-Cañizo, C, Rodríguez-Antolín, A, Guerrero-Ramos, F (2024).

Impact of Tumor Volume and Other Factors on Renal Function After Partial Nephrectomy

Journal of Clinical Medicine. Article. 13(21).
[doi:10.3390/jcm13216305]

Montero-Hidalgo, AJ, Jiménez-Vacas, JM, Gómez-Gómez, E, Porcel-Pastrana, F, Sáez-Martinez, P, Pérez-Gómez, JM, Fuentes-Fayos, AC, Blázquez-Encinas, R, Sánchez-Sánchez, R, González-Serrano, T, Castro, E, López-Soto, PJ, Carrasco-Valiente, J, Sarmento-Cabral, A, Martinez-Fuentes, AJ, Eyras, E, Castaño, JP, Sharp, A, Olmos, D, Gahete, MD, Luque, RM (2024).

SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer

Science Advances. Article. 10(40).
[doi:10.1126/sciadv.ado8231]

Rathkopf DE, Roubaud G, Chi KN, Efstathiou E, Attard G, Olmos D, Small EJ, Saad M, Castro E, Kim W, Wu D, Bertzos K, Dibaj S, Zhang J, Francis P, Smith MR (2024).

Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.

EUROPEAN UROLOGY. Article.
[doi:10.1016/j.eururo.2024.09.003]

Garcia-Ruiz, A, Macarro, C, Zacchi, F, Morales-Barrera, R, Grussu, F, Casanova-Salas, I, Sanguedolce, F, Gonzalez, M, Cresta-Morgado, P, de Albert, M, Garcia-Bennett, J, Marmolejo, D, Planas, J, Roche, S, Mast, R, Zatse, C, Piulats, JM, Herrera-Imbroda, B, Regis, L, Agundez, L, Olmos, D, Calvo, N, Escobar, M, Carles, J, Mateo, J, Perez-Lopez, R (2024).

Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial

EUROPEAN UROLOGY. Editorial Material. 86(3):272-274.
[doi:10.1016/j.eururo.2024.02.016]

Roubaud, G, Attard, G, Boegemann, M, Olmos, D, Trevisan, M, Antoni, L, Pascoe, K, Capone, C, Van Sanden, S, Hashim, M, Palmer, S, Chi, K (2024).

Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer

EUROPEAN JOURNAL OF CANCER. Article. 209:114183-114183.
[doi:10.1016/j.ejca.2024.114183]

del Cañizo, CG, Ginel, IG, Arroba, CMA, Moreno, AD, Arroyo, MH, Antolin, AR, Ramos, FG (2024).

Voided urine cytology is a useful tool predicting non-muscle-invasive bladder cancer risk before surgery

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. Article. 42(8):24615-24621.
[doi:10.1016/j.urolonc.2024.03.014]

Romero-Laorden, N, Lorente, D, de Velasco, G, Lozano, R, Herrera, B, Puente, J, López, PP, Medina, A, Almagro, E, Gonzalez-Billalabeitia, E, Villla-Guzman, JC, González-del-Alba, A, Borrega, P, Laínez, N, Fernández-Freire, A, Hernández, A, Rodriguez-Vida, A, Chirivella, I, Fernandez-Parra, E, López-Campos, F, Pacheco, MI, Morales-Barrera, R, Fernández, O, Villatoro, R, Luque, R, Hernando, S, Castellano, DC, Castro, E, Olmos, D (2024).

Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

European Urology Oncology. Article. 7(3):447-455.
[doi:10.1016/j.euo.2023.09.015]

Olmos, D, Lorente, D, Alameda, D, Cattrini, C, Romero-Laorden, N, Lozano, R, Lopez-Casas, PP, Jambrina, A, Capone, C, Vanden Broecke, AM, Trevisan, M, Van Sanden, S, Juergens, A, Herrera-Imbroda, B, Castro, E (2024).

Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes

ANNALS OF ONCOLOGY. Article. 35(5):458-472.
[doi:10.1016/j.annonc.2024.01.011]

Torres-Jiménez, J, Espinar, JB, de Cabo, HB, Berjaga, MZ, Esteban-Villarrubia, J, Fraile, JZ, Paz-Ares, L (2024).

Targeting KRAS^G12C in Non-Small-Cell Lung Cancer: Current Standards and Developments

DRUGS. Review. 84(5):527-548.
[doi:10.1007/s40265-024-02030-7]

Torres-Jiménez, J, Espinar, JB, de Cabo, HB, Berjaga, MZ, Esteban-Villarrubia, J, Fraile, JZ, Paz-Ares, L (2024).

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments (Apr, 10.1007/s40265-024-02030-7, 2024)

DRUGS. Correction. 84(5):621-621.
[doi:10.1007/s40265-024-02044-1]

Alvarez, SJ, Jiménez, MRI, Ginel, IG, Antolín, AR, del Cañizo, CG (2024).

Abdominal painful mass after prolonged standing: nephroptosis in a 30-year-old woman

LANCET. Editorial Material. 403(10430):946-946.
[doi:10.1016/S0140-6736(24)00197-1]

Casadei, C, Scarpi, E, Conteduca, V, Gurioli, G, Cursano, MC, Brighi, N, Lolli, C, Schepisi, G, Basso, U, Fornarini, G, Bleve, S, Farolfi, A, Altavilla, A, Burgio, SL, Giunta, EF, Gianni, C, Filograna, A, Ulivi, P, Olmos, D, Castro, E, De Giorgi, U (2024).

Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study

European Urology Open Science. Article. 61:44-51.
[doi:10.1016/j.euros.2024.01.015]

Mateo, J, de Bono, JS, Fizazi, K, Saad, F, Shore, N, Sandhu, S, Chi, KN, Agarwal, N, Olmos, D, Thiery-Vuillemin, A, Özgüroglu, M, Mehra, N, Matsubara, N, Joung, JY, Padua, C, Korbenfeld, E, Kang, JY, Marshall, H, Lai, ZW, Barnicle, A, Poehlein, C, Lukashchuk, N, Hussain, M (2024).

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

JOURNAL OF CLINICAL ONCOLOGY. Article. 42(5):571-583.
[doi:10.1200/JCO.23.00339]

Nunes, SP, Morales, L, Rubio, C, Munera-Maravilla, E, Lodewijk, I, Suárez-Cabrera, C, Martínez, VG, Pérez-Escavy, M, Pérez-Crespo, M, Sánchez, MA, Montesinos, E, San José-Enériz, E, Agirre, X, Prósper, F, Pineda-Lucena, A, Henrique, R, Dueñas, M, Correia, MP, Jerónimo, C, Paramio, JM (2024).

Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer

Cell Death Discovery. Article. 10(1):1-1.
[doi:10.1038/s41420-023-01786-3]

2023

Beije, N, Abida, W, Antonarakis, ES, Castro, E, de Wit, R, Fizazi, K, Gillessen, S, Hussain, M, Mateo, J, Morris, MJ, Olmos, D, Sartor, O, Sharp, A, Sweeney, CJ, de Bono, JS (2023).

PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.

EUROPEAN UROLOGY. Editorial Material. 84(3):253-256.
[doi:10.1016/j.eururo.2023.03.038]

Esteban-Villarrubia, J, Ferreiro, CR, Carril-Ajuria, L, Carretero-González, A, Iacovelli, R, Albiges, L, Castellano, D, de Velasco, G (2023).

Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. Article. 41(9).
[doi:10.1016/j.urolonc.2023.05.002]

Chi, KN, Sandhu, S, Smith, MR, Attard, G, Saad, M, Olmos, D, Castro, E, Roubaud, G, Gomes, AJPD, Small, EJ, Rathkopf, DE, Gurney, H, Jung, W, Mason, GE, Dibaj, S, Wu, D, Diorio, B, Urtishak, K, del Corral, A, Francis, P, Kim, W, Efstathiou, E (2023).

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

ANNALS OF ONCOLOGY. Article. 34(9):772-782.
[doi:10.1016/j.annonc.2023.06.009]

Smith, MR, Sandhu, S, George, DJ, Chi, KN, Saad, F, Thiery-Vuillemin, A, Stáhl, O, Olmos, D, Danila, DC, Gafanov, R, Castro, E, Moon, H, Joshua, AM, Mason, GE, Espina, BM, Liu, Y, Lopez-Gitlitz, A, Francis, P, Bevans, KB, Fizazi, K (2023).

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects

Journal of Managed Care & Specialty Pharmacy. Article. 29(7):758-768.

Chi, KN, Rathkopf, D, Smith, MR, Efstathiou, E, Attard, G, Olmos, D, Lee, JY, Small, EJ, Pereira de Santana Gomes AJ, Roubaud, G, Saad, M, Zurawski, B, Sakalo, V, Mason, GE, Francis, P, Wang G, Wu, D, Diorio, B, Lopez-Gitlitz, A, Sandhu, S (2023).

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.

JOURNAL OF CLINICAL ONCOLOGY. Article. 41(18):3339.
[doi:10.1200/JCO.22.01649]

Matsubara, N, de Bono, J, Sweeney, C, Chi, KN, Olmos, D, Sandhu, S, Massard, C, Garcia, J, Chen, G, Harris, A, Schenkel, F, Sane, R, Hinton, H, Bracarda, S, Sternberg, CN (2023).

Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer

CLINICAL GENITOURINARY CANCER. Article. 21(2):230.
[doi:10.1016/j.clgc.2023.01.001]

Esteban-Villarrubia, J, Torres-Jiménez, J, Bueno-Bravo, C, García-Mondaray, R, Subiela, JD, Gajate, P (2023).

Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer

Cancers. Review. 15(3).
[doi:10.3390/cancers15030566]

Chi, KN, Barnicle, A, Sibilla, C, Lai, ZW, Corcoran, C, Barrett, JC, Adelman, CA, Qiu, P, Easter, A, Dearden, S, Oxnard, GR, Agarwal, N, Azad, A, de Bono, J, Mateo, J, Olmos, D, Thiery-Vuillemin, A, Harrington, EA (2023).

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.

CLINICAL CANCER RESEARCH. Article. 29(1):81-91.
[doi:10.1158/1078-0432.CCR-22-0931]